Head-to-head · free

BioStem Technologies, Inc. vs Quest Diagnostics

BSEM vs DGX — return on capital, cash generation, margins and balance sheet side by side.

BSEM

0 / 0

measures where BSEM leads

DGX

0 / 0

measures where DGX leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureBSEMDGX · FY2025
Revenue—$11.0B
Net income—$992.0M
Revenue growth (yearly, multi-year)—0.6%
Free cash flow—$1.4B
Free cash flow margin—12.3%
Net cash / (debt)——
ROIC—8.5%
Return on equity—14.2%
Gross margin—33.2%
Operating margin—14.1%
Net debt / EBITDA—2.57x

Figures are as reported by each company; latest fiscal year shown.

Where BioStem Technologies, Inc.'s cash went

Not reported yet.

Full BSEM profile →

Where Quest Diagnostics's cash went (FY2025)

Capital spending
$527.0M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full DGX profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons